ALKS

Alkermes plc
CAPPED RATING

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes plc (ALKS) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Growth (D+). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 34.4
EV / EBITDA 30.7
Rev Growth YoY 21.8%
Gross Margin 87.0%
Price Return 3M -6.0%
Price Return 12M 50.0%
Catalyst Signal 0.00
Market Cap $7.8B
TTM Revenue $1.8B
Price / Sales 4.5
ROE -0.0%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C (2.5) D+ (1.6) A- (3.9) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-10 C (2.4) D+ (1.6) A- (3.9) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-03 D+ (1.8) C (2.2) A- (3.9) B- (3.1) C+ (2.7) C+ (2.7)
2026-10-27 D+ (1.8) C (2.2) A- (3.9) C+ (2.8) C+ (2.6) C+ (2.7)
2026-10-20 C- (1.9) C (2.2) A- (3.9) C+ (2.8) C+ (2.6) C+ (2.7)
Page 1 of 8
…